Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients

In a retrospective study of 50 alopecia areata (AA) patients, diphenylcyclopropenone (DPCP) was evaluated for its efficacy, with a median treatment duration of 3 years. Results showed that 47% of patients experienced hair regrowth within the first 6 months, and treatment success (≥50% terminal hair regrowth) was achieved in 71% of alopecia totalis and 56% of alopecia universalis patients. Poor treatment outcomes were significantly associated with the extent of hair loss before treatment, history of thyroid disease, and extent of body hair involvement. Relapse occurred in 44% of patients, particularly those with a history of thyroid disease. Common side effects included itching, rash, and local lymphadenopathy. The study concluded that DPCP is a viable treatment option that can be managed at home and should be continued for at least 2 years before considering termination.